Sun Min Lim1, Min Hee Hong1, Sang-Jun Ha2, Daehee Hwang3, Sehyun Chae4, Yoon Woo Koh5, Eun Chang Choi5, Se-Heon Kim5, Da-Hee Kim5, Sun Och Yoon6, Hye Ryun Kim7. 1. Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea. 2. Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul, Republic of Korea. 3. Department of Biological Sciences, Seoul National University, Seoul, 08826, Republic of Korea. 4. Korea Brain Bank, Korea Brain Research Institute, Daegu, 41062, Republic of Korea. 5. Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul, Republic of Korea. 6. Department of Pathology, Yonsei University College of Medicine, Seoul, Republic of Korea. SOYOON@yuhs.ac. 7. Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea. nobelg@yuhs.ac.
Abstract
PURPOSE: We aimed to investigate the prognostic value of multiple immune cell markers including programmed death-ligand 1 (PD-L1) and poliovirus receptor (PVR) in head and neck squamous cell carcinoma (HNSCC) using archival tumor tissues METHODS: Patients diagnosed with HNSCC who have undergone surgical resection in 2005-2012 were included. Correlations between PVR and PD-L1 expression and patient characteristics were analyzed by analysis of variance. The Kaplan-Meier method and log-rank test were used to estimate survival. P values < 0.05 were considered statistically significant. RESULTS: In total, 375 primary tumor tissues were analyzed using immunohistochemistry. High PVR expression was associated with a poor prognosis in terms of overall survival (OS) and recurrence-free survival (RFS), and tumors with high PVR expression were associated with a short OS. PD-L1 tumor expression did not have a prognostic impact on survival. Univariate analysis revealed that OS and RFS were affected by age and p16 and PVR expression; multivariate analysis revealed that age and p16 and PVR expression were the most important determinants of RFS. CONCLUSION: PVR overexpression is a poor prognostic factor in patients with HNSCC and co-targeting PVR and PD-L1 may be a promising therapeutic option that needs further investigation.
PURPOSE: We aimed to investigate the prognostic value of multiple immune cell markers including programmed death-ligand 1 (PD-L1) and poliovirus receptor (PVR) in head and neck squamous cell carcinoma (HNSCC) using archival tumor tissues METHODS:Patients diagnosed with HNSCC who have undergone surgical resection in 2005-2012 were included. Correlations between PVR and PD-L1 expression and patient characteristics were analyzed by analysis of variance. The Kaplan-Meier method and log-rank test were used to estimate survival. P values < 0.05 were considered statistically significant. RESULTS: In total, 375 primary tumor tissues were analyzed using immunohistochemistry. High PVR expression was associated with a poor prognosis in terms of overall survival (OS) and recurrence-free survival (RFS), and tumors with high PVR expression were associated with a short OS. PD-L1 tumor expression did not have a prognostic impact on survival. Univariate analysis revealed that OS and RFS were affected by age and p16 and PVR expression; multivariate analysis revealed that age and p16 and PVR expression were the most important determinants of RFS. CONCLUSION:PVR overexpression is a poor prognostic factor in patients with HNSCC and co-targeting PVR and PD-L1 may be a promising therapeutic option that needs further investigation.
Authors: K Kian Ang; Jonathan Harris; Richard Wheeler; Randal Weber; David I Rosenthal; Phuc Felix Nguyen-Tân; William H Westra; Christine H Chung; Richard C Jordan; Charles Lu; Harold Kim; Rita Axelrod; C Craig Silverman; Kevin P Redmond; Maura L Gillison Journal: N Engl J Med Date: 2010-06-07 Impact factor: 91.245
Authors: Haidong Dong; Gefeng Zhu; Koji Tamada; Dallas B Flies; Jan M A van Deursen; Lieping Chen Journal: Immunity Date: 2004-03 Impact factor: 31.745
Authors: Joshua Bauml; Tanguy Y Seiwert; David G Pfister; Francis Worden; Stephen V Liu; Jill Gilbert; Nabil F Saba; Jared Weiss; Lori Wirth; Ammar Sukari; Hyunseok Kang; Michael K Gibson; Erminia Massarelli; Steven Powell; Amy Meister; Xinxin Shu; Jonathan D Cheng; Robert Haddad Journal: J Clin Oncol Date: 2017-03-22 Impact factor: 44.544
Authors: Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi Journal: Nature Date: 2014-11-27 Impact factor: 49.962
Authors: Robert L Ferris; George Blumenschein; Jerome Fayette; Joel Guigay; A Dimitrios Colevas; Lisa Licitra; Kevin Harrington; Stefan Kasper; Everett E Vokes; Caroline Even; Francis Worden; Nabil F Saba; Lara C Iglesias Docampo; Robert Haddad; Tamara Rordorf; Naomi Kiyota; Makoto Tahara; Manish Monga; Mark Lynch; William J Geese; Justin Kopit; James W Shaw; Maura L Gillison Journal: N Engl J Med Date: 2016-10-08 Impact factor: 91.245
Authors: Alice L Hung; Russell Maxwell; Debebe Theodros; Zineb Belcaid; Dimitrios Mathios; Andrew S Luksik; Eileen Kim; Adela Wu; Yuanxuan Xia; Tomas Garzon-Muvdi; Christopher Jackson; Xiaobu Ye; Betty Tyler; Mark Selby; Alan Korman; Bryan Barnhart; Su-Myeong Park; Je-In Youn; Tamrin Chowdhury; Chul-Kee Park; Henry Brem; Drew M Pardoll; Michael Lim Journal: Oncoimmunology Date: 2018-05-24 Impact factor: 8.110